Webinar: InMed Pharmaceuticals

Published on 5 October 2021

InMed Pharmaceuticals (INM) is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol, and is developing IntegraSyn to produce pharmaceutical-grade cannabinoids. InMed recently announced that it has entered into a definitive agreement to acquire BayMedica, a revenue-stage biotechnology company leveraging synthetic biology and pharmaceutical chemistry to develop an efficient, scalable and proprietary platform to produce high-quality, rare cannabinoids for consumer applications. The combined company will be a market leader in the manufacture of rare cannabinoids.

In this webinar, InMed chief executive officer Eric Adams and BayMedica chief executive officer Dr Shane Johnson discuss the acquisition and their plans for the newly combined company.

Share this with friends and colleagues